The presence of the tyrosine kinase-AKT-mTOR axis in the carcinogenesis of cholangiocarcinoma (Chung et al., 2009) has provided us with an opportunity to evaluate the therapeutic role of an mTOR inhibitor, rad001, in the management of this disease. The gene discussed is MTOR; the disease is cholangiocarcinoma.